Innovation in traditional medicine is not easily compatible with standard measures, such as patents and clinical trials. Especially, in the current context of COVID-19, there is a renewed interest in alternative cures from traditional medicine. While the ‘historical capital’ associated with traditional medicine systems like Ayurveda creates a ready market for medicinal formulations, possibilities of innovation remain uncaptured. Within the space of traditional medicines, Ayurveda has, in recent years, resulted in a plethora of medicines: both proprietary formulations as well as ‘pill-ized’ versions of standard classical herbs. We conduct a detailed investigation of this issue using a two-pronged strategy. First is a qualitative investigation through a primary survey of Ayurveda practitioners based in Delhi and Kerala in 2018, using the snowball sampling technique, to understand what innovation should mean for Ayurvedic pharmacopeia. Second is our quantitative analysis using the hedonic method, which checks for commercial incentives reflected in retail prices of Ayurvedic formulations, which incorporate varying degrees of innovation. We find the existence of commercial profit-making incentives, and that innovation in Ayurveda is synonymous with improvements in utility for patients by making medicines more palatable and travel friendly. We conduct robustness checks by contrasting the results from our parametric specification with a non-parametric chi-square automatic interaction detector (CHAID) analysis. However, we do not find scientific evidence supporting the discovery and efficacy of these medicines. Public investments in efficacy standards that strengthen the linkages between research and commercial drug discovery are necessary to infuse innovation in the large pharmacopoeia of traditional medicine systems like Ayurveda.
Using COVID-19 as the backdrop, this article investigates different trade-offs in terms of pecuniary and time costs in drug development across different branches of medicine. South Asian countries as well as China have a rich history of practicing traditional and alternative medicine. However, modern biomedicine as well as traditional medicine comes with certain procedural requirements, which make immediate responses to a pandemic difficult. Clinical trials in biomedicine are costly, mostly in terms of time. On the other hand, a lack of these standards, as in the case of many alternative medicines, does not come with the promise of low-cost cures for the viral pandemic. Any modification of the standards in pharmaceutical testing has resulted in avoidable controversies at all stages of drug discovery, be it in research papers, or in clinical trials, or in the sale of actual medicine itself. Non-pharmaceutical intervention, with different economic impacts, becomes imperative.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.